Alerts

Takeda Pharmaceuticals Australia has issued a product alert for Vyvanse capsules due to minor packaging errors. The medication is safe to use as prescribed.

The supply of Ozempic (semaglutide) will continue to be limited until 31 December 2025

Pharmacists can use a Serious Scarcity Substitution Instrument (SSSI) to dispense Protaphane Penfill human insulin in the place of a Protaphane InnoLet cartridge.

A shortage of Bicillin L-A 1.2 million unit prefilled syringes is anticipated from 20 December 2024 to 10 January 2025. A PBS-listed substitute product is available.

Pharmacists may dispense alternative brands or strengths without a new prescription.

Metalyse is now available for use in all clinical settings.

We have made a new Serious Scarcity Substitution Instrument to help manage the shortage and upcoming discontinuation of Ryzodeg 70/30 FlexTouch insulin.

The new KwikPen presentation of Mounjaro is now available but supply of all strengths of Mounjaro vials remains limited.

We have been advised that Novo Nordisk will gradually discontinue some of its earlier generation insulin products over the next 2 years.

Shortage resolved

Pharmaceutical company Novo Nordisk has advised us that a new brand of semaglutide approved for chronic weight management, Wegovy, will be available in Australia from early August 2024.

Medicine shortage alert

Shortage resolved

Due to Oxynorm being reinstated in Australia and Ordine shortage extension

Current shortage of Vyvanse 20 mg and anticipated shortage of Vyvanse 60mg capsules.

Fluoxetine substitution instrument has been extended.

extension of SSSI

Pharmacists can now substitute one Orencia 125 mg product for the other

Find out about the shortage of Orencia (abatacept) 125 mg/mL ClickJect autoinjector and prefilled syringe for subcutaneous injection.

All strengths of Vyvanse capsules are now available.

This shortage has been extended

The shortage of Vyvanse 60 mg has been extended to 30 April 2024

Pfizer Australia has advised that the shortage of Bicillin L-A prefilled syringe for injection will continue until mid-2024, so we have approved the importation and supply of a second overseas-registered product, Extencilline benzathine benzylpenicillin 1.2 million unit vial (France), until 30 September 2024.

Metalyse (tenecteplase) 40 mg for injection is to be discontinued; supply of Metalyse 50 mg for injection is not affected.

The shortages of these products have been extended by the sponsor.